http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2531133-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_28e51a279fa3515d1e152f2e1f0d8f9b |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-007 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-06 |
| filingDate | 2013-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a1f7f3eb2adcbb6a23b00749d4428c9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81ec7de632904bae8cd4509867f846f7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_072946636923d572568f47564fe7611e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_644f96af2e73669b92e154e8014520b4 |
| publicationDate | 2014-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2531133-C1 |
| titleOfInvention | Method of treating secondary glaucoma caused by silicone emulsification |
| abstract | FIELD: medicine. n SUBSTANCE: invention refers to medicine, namely to ophthalmic surgery, and can be used for treating secondary glaucoma caused by silicone emulsification after subtotal vitrectomy with introducing silicone oil in retinal detachment. That is ensured by forming conjunctival and superficial scleral flaps. Ex-PRESS microshunt is implanted into the sclera within the cornea to the sclera transition. Then, a hydrogel drain tube is laid on the scleral bed, under the scleral flap in parallel to a limb at 3 mm away in the distal direction from the microshunt . The scleral flap together with the hydrogel drain tube is fixed with one interrupted suture in the centre. One sclero-scleral suture is applied on each side of the scleral flap. Free ends of the hydrogel drain tube are smoothed in between the sutures. The surgical procedure is completed. On the first postoperative day, 5-fluoruracil 0.2-0.3 ml is introduced subconjunctivally into a filtering bleb. Further, once a week for 5-7 weeks, 5-fluoruracil is introduced in the above dose in the filtering bleb. n EFFECT: method provides recovering the intraocular fluid outflow tracts, enabling the more complete removal of emulsified silicone from the anterior eye chamber by creating the greater volume of the intrascleral cavity that ensures the more stable antihypertensive effect and preserving the visual functions. n 2 ex, 1 dwg |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2688960-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2576815-C1 |
| priorityDate | 2013-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 25.